Living Cell Technologies Ltd., of Sydney, said 81 weeks after treatment all four patients who took part in the phase I/IIa trial of Parkinson's disease cell therapy candidate Ntcell showed reversal of the progression of disease, as measured by the Unified Parkinson's Disease Rating Scale. All four patients remain well and there are no safety concerns.